Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BP31
- Development stage
- Preclinical
- Lead developer
- CuraTeQ Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
BP31 is an undisclosed biosimilar monoclonal antibody under development by CuraTeQ Biologics, a subsidiary of Aurobindo Pharma. It is being developed for the treatment of immunological and inflammatory conditions, specifically plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. The drug is currently in preclinical development (CMC development phase).
Beyond the preview
Go deeper on BP31.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BP31.